Stockreport

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSens [Read more]